Skip to main content

Jeff P. Sharman

Jeff Sharman, MD
Conference Coverage
12/11/2023
At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...
At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology